Transcriptional expression of survivin and its splice variants in brain tumors in humans

Yoshitaka Yamada, Toshihiko Kuroiwa, Toshimasa Nakagawa, Yoshinaga Kajimoto, Takehiko Dohi, Haruhito Azuma, Motomu Tsuji, Kazuhiro Kami, Shin Ichi Miyatake

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Object. Survivin, one of the apoptosis inhibitor proteins, has been detected in most cancers in humans. In addition, two splice variants (survivin-2B and survivin-ΔEx3) have been identified. The authors investigated the transcription levels of survivin messenger (m)RNA and its splice variants in nine tumor cell lines, including gliomas, and in 25 brain tumor samples, by performing quantitative reverse transcription-polymerase chain reaction. The correlation between transcript expression levels and pathological findings were also analyzed. Methods. Transcription levels were measured using primer pairs specific for survivin and either of its splice variants and were normalized to the glyceraldehyde 6-phosphate dehydrogenase. Among the tumor cell lines tested, glioblastoma cell lines showed the highest levels of survivin expression. Among brain tumor samples studied, survivin was preferentially expressed in malignant brain tumors and gliomas. The relative expression level of survivin-ΔEx3/survivin was significantly higher in malignant than in benign brain tumor samples. Expression patterns were dominant for survivin-ΔEx3 in malignant brain tumors and dominant for survivin-2B in benign ones. A significant linear correlation between survivin mRNA expression and MIB-1 labeling index was demonstrated in all brain tumor samples. Conclusions. The authors' results indicate that quantifying the levels of survivin and its splice variants is useful for the prediction of the cell biological malignancy of gliomas, independent of their pathological features.

Original languageEnglish (US)
Pages (from-to)738-745
Number of pages8
JournalJournal of neurosurgery
Volume99
Issue number4
DOIs
StatePublished - Oct 1 2003

Fingerprint

Brain Neoplasms
Glioma
Tumor Cell Line
Inhibitor of Apoptosis Proteins
Glyceraldehyde
Messenger RNA
Glioblastoma
Reverse Transcription
Neoplasms
Oxidoreductases
Phosphates
Cell Line
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Yamada, Y., Kuroiwa, T., Nakagawa, T., Kajimoto, Y., Dohi, T., Azuma, H., ... Miyatake, S. I. (2003). Transcriptional expression of survivin and its splice variants in brain tumors in humans. Journal of neurosurgery, 99(4), 738-745. https://doi.org/10.3171/jns.2003.99.4.0738
Yamada, Yoshitaka ; Kuroiwa, Toshihiko ; Nakagawa, Toshimasa ; Kajimoto, Yoshinaga ; Dohi, Takehiko ; Azuma, Haruhito ; Tsuji, Motomu ; Kami, Kazuhiro ; Miyatake, Shin Ichi. / Transcriptional expression of survivin and its splice variants in brain tumors in humans. In: Journal of neurosurgery. 2003 ; Vol. 99, No. 4. pp. 738-745.
@article{262575437c034d7db336bbceeb74e971,
title = "Transcriptional expression of survivin and its splice variants in brain tumors in humans",
abstract = "Object. Survivin, one of the apoptosis inhibitor proteins, has been detected in most cancers in humans. In addition, two splice variants (survivin-2B and survivin-ΔEx3) have been identified. The authors investigated the transcription levels of survivin messenger (m)RNA and its splice variants in nine tumor cell lines, including gliomas, and in 25 brain tumor samples, by performing quantitative reverse transcription-polymerase chain reaction. The correlation between transcript expression levels and pathological findings were also analyzed. Methods. Transcription levels were measured using primer pairs specific for survivin and either of its splice variants and were normalized to the glyceraldehyde 6-phosphate dehydrogenase. Among the tumor cell lines tested, glioblastoma cell lines showed the highest levels of survivin expression. Among brain tumor samples studied, survivin was preferentially expressed in malignant brain tumors and gliomas. The relative expression level of survivin-ΔEx3/survivin was significantly higher in malignant than in benign brain tumor samples. Expression patterns were dominant for survivin-ΔEx3 in malignant brain tumors and dominant for survivin-2B in benign ones. A significant linear correlation between survivin mRNA expression and MIB-1 labeling index was demonstrated in all brain tumor samples. Conclusions. The authors' results indicate that quantifying the levels of survivin and its splice variants is useful for the prediction of the cell biological malignancy of gliomas, independent of their pathological features.",
author = "Yoshitaka Yamada and Toshihiko Kuroiwa and Toshimasa Nakagawa and Yoshinaga Kajimoto and Takehiko Dohi and Haruhito Azuma and Motomu Tsuji and Kazuhiro Kami and Miyatake, {Shin Ichi}",
year = "2003",
month = "10",
day = "1",
doi = "10.3171/jns.2003.99.4.0738",
language = "English (US)",
volume = "99",
pages = "738--745",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "4",

}

Yamada, Y, Kuroiwa, T, Nakagawa, T, Kajimoto, Y, Dohi, T, Azuma, H, Tsuji, M, Kami, K & Miyatake, SI 2003, 'Transcriptional expression of survivin and its splice variants in brain tumors in humans', Journal of neurosurgery, vol. 99, no. 4, pp. 738-745. https://doi.org/10.3171/jns.2003.99.4.0738

Transcriptional expression of survivin and its splice variants in brain tumors in humans. / Yamada, Yoshitaka; Kuroiwa, Toshihiko; Nakagawa, Toshimasa; Kajimoto, Yoshinaga; Dohi, Takehiko; Azuma, Haruhito; Tsuji, Motomu; Kami, Kazuhiro; Miyatake, Shin Ichi.

In: Journal of neurosurgery, Vol. 99, No. 4, 01.10.2003, p. 738-745.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transcriptional expression of survivin and its splice variants in brain tumors in humans

AU - Yamada, Yoshitaka

AU - Kuroiwa, Toshihiko

AU - Nakagawa, Toshimasa

AU - Kajimoto, Yoshinaga

AU - Dohi, Takehiko

AU - Azuma, Haruhito

AU - Tsuji, Motomu

AU - Kami, Kazuhiro

AU - Miyatake, Shin Ichi

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Object. Survivin, one of the apoptosis inhibitor proteins, has been detected in most cancers in humans. In addition, two splice variants (survivin-2B and survivin-ΔEx3) have been identified. The authors investigated the transcription levels of survivin messenger (m)RNA and its splice variants in nine tumor cell lines, including gliomas, and in 25 brain tumor samples, by performing quantitative reverse transcription-polymerase chain reaction. The correlation between transcript expression levels and pathological findings were also analyzed. Methods. Transcription levels were measured using primer pairs specific for survivin and either of its splice variants and were normalized to the glyceraldehyde 6-phosphate dehydrogenase. Among the tumor cell lines tested, glioblastoma cell lines showed the highest levels of survivin expression. Among brain tumor samples studied, survivin was preferentially expressed in malignant brain tumors and gliomas. The relative expression level of survivin-ΔEx3/survivin was significantly higher in malignant than in benign brain tumor samples. Expression patterns were dominant for survivin-ΔEx3 in malignant brain tumors and dominant for survivin-2B in benign ones. A significant linear correlation between survivin mRNA expression and MIB-1 labeling index was demonstrated in all brain tumor samples. Conclusions. The authors' results indicate that quantifying the levels of survivin and its splice variants is useful for the prediction of the cell biological malignancy of gliomas, independent of their pathological features.

AB - Object. Survivin, one of the apoptosis inhibitor proteins, has been detected in most cancers in humans. In addition, two splice variants (survivin-2B and survivin-ΔEx3) have been identified. The authors investigated the transcription levels of survivin messenger (m)RNA and its splice variants in nine tumor cell lines, including gliomas, and in 25 brain tumor samples, by performing quantitative reverse transcription-polymerase chain reaction. The correlation between transcript expression levels and pathological findings were also analyzed. Methods. Transcription levels were measured using primer pairs specific for survivin and either of its splice variants and were normalized to the glyceraldehyde 6-phosphate dehydrogenase. Among the tumor cell lines tested, glioblastoma cell lines showed the highest levels of survivin expression. Among brain tumor samples studied, survivin was preferentially expressed in malignant brain tumors and gliomas. The relative expression level of survivin-ΔEx3/survivin was significantly higher in malignant than in benign brain tumor samples. Expression patterns were dominant for survivin-ΔEx3 in malignant brain tumors and dominant for survivin-2B in benign ones. A significant linear correlation between survivin mRNA expression and MIB-1 labeling index was demonstrated in all brain tumor samples. Conclusions. The authors' results indicate that quantifying the levels of survivin and its splice variants is useful for the prediction of the cell biological malignancy of gliomas, independent of their pathological features.

UR - http://www.scopus.com/inward/record.url?scp=0141608911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141608911&partnerID=8YFLogxK

U2 - 10.3171/jns.2003.99.4.0738

DO - 10.3171/jns.2003.99.4.0738

M3 - Article

C2 - 14567610

AN - SCOPUS:0141608911

VL - 99

SP - 738

EP - 745

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 4

ER -